Research Evidence Anecdotal Efficacy Side Effects Price Dosing & Protocol Peptide Deep Dive Regulatory Safety Notes

Survodutide

Survodutide has Phase 2 RCT-grade evidence for Obesity. Off-label / exploratory data exists for 3 additional indications (Pharmacokinetic / healthy volunteer studies; Overweight).

Research Evidence

Evidence shape

Survodutide has Phase 2 RCT-grade evidence for Obesity. Off-label / exploratory data exists for 3 additional indications (Pharmacokinetic / healthy volunteer studies; Overweight).

Depthhow much

19 registered trials

16 completed · 3 with posted results · 3 recruiting / active · combined n=1095

Breadthhow many areas

7 indications mapped

3 with results · 3 thin / exploratory · 1 animal-only · 2 single-trial long-tail

Qualityhow rigorous

Highest tier: Phase 3

3 blinded with results · AE rows aggregated from 3 trials · 6 linked publications on registered trials

Breadth and depth20 rows captured

Human

direct clinical signal

19

Animal

translational support

1

In vitro

mechanistic support

0

HighMediumLow

Anecdotal efficacy

Weight loss & obesity management

9 linked reports sit in this bucket. The captured signal currently skews positive, with 77.8% positive, 22.2% mixed, and 0% negative.

1-4 of 9

+“Week 2 I lost a lb and now week 3 down 2.”r/Retatrutide · 1 upvotes +“I’ve continued to lose weight (and improve my insulin sensitivity, it's more or less normal now).”r/Retatrutide · 5 upvotes +“Appetite suppression is great on 1.2mg”r/survodutide · 3 upvotes ~“I stopped losing after about a year and regained a small amount, but it's pretty easy to maintain if I even just vaguely try. My appetite feels appropriate.”r/antidietglp1 · 3 upvotes

Side effects

Clinical research side effects

Anecdotal side effects

Side effect source data

121 linked sources are available across clinical rows and community reports.

Clinical 97Anecdotal 24

1-4 of 121

ClinicalNausea / GI

Diarrhoea — 24.0%NCT04153929 · BI 456906 0.3 mg (n=50) · placebo arm: 11.9% (7/59)

ClinicalNausea / GI

Nausea — 20.0%NCT04153929 · BI 456906 0.3 mg (n=50) · placebo arm: 8.5% (5/59)

ClinicalNausea / GI

Vomiting — 14.0%NCT04153929 · BI 456906 0.3 mg (n=50) · placebo arm: 5.1% (3/59)

ClinicalOther

Decreased appetite — 12.0%NCT04153929 · BI 456906 0.3 mg (n=50) · placebo arm: 3.4% (2/59)

Price

1

Nexaph

100 mg

$134.00

$1.34/mg

2

Prism Aminos

10 mg

$24.25

$2.42/mg

3

High Purity Peptides

100 mg

$300.00

$3/mg

4

Purerxpeptides

20 mg

$95.00

$4.75/mg

5

Kensington Labs

10 mg

$67.23

$6.72/mg

6

Edge Peptides

100 mg

$690.00

$6.9/mg

price offers can be sorted by column

1-6 of 22

Dosing & Protocol

How Survodutide is dosed across research, clinician, and community sources — each evidence tier kept separate so the dose range, frequency, timing, and cycling stay visible without flattening different levels of evidence.

Research trials

Published clinical-trial protocols · n = 16

Typical dose

No quantified dose captured for this tier.

Frequency: weekly
Timing: unspecified
Route: subQ
Cycle: unspecified

16 completed trials identified; trial dosing not reliably extracted from registry data.

8 sources

Clinician practice

Doctor & published-protocol guidance · n = 2

Typical dose

6 mg3.6 mg – 6 mg

3.6 mg
6 mg

Frequency: weekly
Timing: unspecified
Route: subQ
Cycle: unspecified

Clinician protocols dose 3.6 mg–6 mg weekly subQ (2 sources).

2 sources

Anecdotal

Community-reported real-world use · n = 9

Typical dose

No quantified dose captured for this tier.

No structured protocol details captured for this tier yet.

Community reports on Survodutide for weight loss and obesity management are largely positive, with 77.8% of 9 reports indicating positive outcomes.

Dose & protocol sources

10 linked sources are available across the research, clinician, and community tiers. Each card states what that source says, with a link to it.

Research trials 8Clinician practice 2Anecdotal 0

Research trialsNCT04667377

Percentage Change in Body Weight From Baseline to Week 46

NCT04667377 · Phase 2 ↗

Research trialsNCT06214741

Percentage change in body weight from baseline to Week 52

NCT06214741 · Phase 3 ↗

Research trialsNCT06176365

Percentage change in body weight from baseline to Week 76

NCT06176365 · Phase 3 ↗

Research trialsNCT03591718

Cumulative number [N (%)] of patients withdrawn from up-titration by up-titration scheme

NCT03591718 · Phase 1 ↗

Research trialsNCT06352424

Blood Oxygen Level Dependent (BOLD) signal changes following treatment with single dose of BI 1820237 alone, BI 456906 alone, and combination of BI 1820237 + BI 456906 versus placebo

NCT06352424 · Phase 1 ↗

Research trialsNCT04771273

Improvement (Yes/ no) From Baseline in Liver Histological Findings Based on Liver Biopsy After 48 Weeks of Treatment in Patients With NASH (NAS ≥ 4, Fibrosis F1-F3) - Actual Maintenance Treatment

NCT04771273 · Phase 2 ↗

Research trialsNCT04153929

Absolute Change in HbA1c From Baseline to 16 Weeks

NCT04153929 · Phase 2 ↗

Research trialsNCT05751226

Percentage of treatment-emergent adverse events

NCT05751226 · Phase 1 ↗

Clinician practicePeptide Dosing Protocols

Dose 6 mgFrequency dailyRoute subQCycle 4-12 weeks

Peptide Dosing Protocols — Garret Grant (peptidedosingprotocols.com) ↗

Clinician practicePeptide List

Dose 3.6 mgFrequency weeklyRoute subQ

Peptide List — Longevity Insights LLC (peptidelist.org) ↗

Peptide Deep Dive

Peptide Deep Dive is not projected for this peptide yet.

Peptide feedback

0 forum replies

Live community discussion for Survodutide, shown here in the site layout and continued on the TVR forum.

Add feedback

No peptide feedback yet

Start the peptide feedback thread on the TVR forum.